Our data are in line with a earlier study investigating ECG changes after nivolumab treatment in sound tumors [31] and confirm that the combination of CTLA-4 and PD-1 inhibitors increases the risk for the development of cardiac irAEs when compared to monotherapy [30]

Our data are in line with a earlier study investigating ECG changes after nivolumab treatment in sound tumors [31] and confirm that the combination of CTLA-4 and PD-1 inhibitors increases…